Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 66.6%

Neg 0% Neu 0% Pos 66.6%

Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.